ADPTのチャート
ADPTの企業情報
| symbol | ADPT |
|---|---|
| 会社名 | Adeptus Health Inc （アデプタス・ヘルス） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | ― 医療関連（Health Care） |
| 概要 | ― アデプタス・ヘルスは米国の救急ケアプロバイダ―。テキサス州ヒュ―ストン、ダラス/フォ―トワ―ス、サンアントニオ、オ―スチン、コロラド州デンバ―とコロラドスプリングス、およびアリゾナ州フェニックスに独立型急病診療所｢ファ―スト・チョイス・エマ―ジェンシ―・ル―プ｣を所有、運営する。 Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. |
| 本社所在地 | 2941 Lake Vista Drive Lewisville TX 75067 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 41699 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 3202人 |
| url | www.adhc.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | |
| 売上高 | |
| 企業価値(EV) | |
| 当期純利益 | |
| 決算概要 | ― |
| symbol | ADPT |
| 会社名 | Adeptus Health Inc （アダプティブ･バイオテクノロジーズ(Adaptive Biotechnologies Corp)） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | バイオテクノロジー & メディカル リサーチ 医療関連 （Health Care） |
| 概要 | ― アデプタス・ヘルスは米国の救急ケアプロバイダ―。テキサス州ヒュ―ストン、ダラス/フォ―トワ―ス、サンアントニオ、オ―スチン、コロラド州デンバ―とコロラドスプリングス、およびアリゾナ州フェニックスに独立型急病診療所｢ファ―スト・チョイス・エマ―ジェンシ―・ル―プ｣を所有、運営する。 Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. |
| 本社所在地 | 2941 Lake Vista Drive Lewisville TX 75067 USA |
| 代表者氏名 | Chad M. Robins |
| 代表者役職名 | Executive Chairman Chief Executive Officer Co-Founder |
| 電話番号 | +1 206-659-0067 |
| 設立年月日 | 41699 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 3202人 |
| url | www.adhc.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） -70.60000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 4567.03600 |
| 売上高 | 売上高（百万ドル） 85.07100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 4026.77700 |
| 当期純利益 | 当期純利益（百万ドル） -69.57000 |
| 決算概要 | BRIEF: For the fiscal year ended 31 December 2019 Adaptive Biotechnologies Corp revenues increased 53% to $85.1M. Net loss applicable to common stockholders increased 50% to $69.6M. Revenues reflect Development revenue increase of 83% to $41.6M Sequencing revenue increase of 32% to $43.5M. Higher net loss reflects Research and development - Balancing increase of 84% to $66.8M (expense). |
ADPTのテクニカル分析
ADPTのニュース
Adaptive Biotechnologies Corporation (ADPT) Q3 2022 Earnings Call Transcript 2022/11/04 02:36:04 Seeking Alpha
Adaptive Biotechnologies Corporation (NASDAQ:NASDAQ:ADPT) Q3 2022 Earnings Conference Call November 03, 2022, 04:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins -…
Adaptive Biotechnologies GAAP EPS of -$0.32 beats by $0.06, revenue of $47.8M misses by $0.61M; narrows outlook 2022/11/03 20:31:06 Seeking Alpha
Adaptive Biotechnologies press release (ADPT): Q3 GAAP EPS of -$0.32 beats by $0.06.Revenue of $47.8M (+21.0% Y/Y) misses by $0.61M.Adaptive Biotechnologies narrows full year…
November 3, 2022 4:30 PM EDT : Adaptive Biotechnologies Third Quarter Financial Results 2022/11/03 20:30:00 Adaptive Biotechnologies
The Investor Relations website contains information about Adaptive Biotechnologies''s business for stockholders, potential investors, and financial analysts.
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results 2022/11/03 20:05:00 GlobeNewswire
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2022.
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) 8.10% Incline Turns Investors Off From Company Stock 2022/11/02 15:00:00 Stocks Register
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) traded at $8.41 at close of the session on Tuesday, 11/01/22, made an upward move of 8.10% on its previous day’s price. Looking at the stock we see that its previous close was $7.78 and the beta (5Y monthly) reads 0.91 with the day’s price range being $7.89 – $8.54. In … Adaptive Biotechnologies Corporation (NASDAQ: ADPT) 8.10% Incline Turns Investors Off From Company Stock Read More »
Adaptive Biotechnologies Corporation Shares Are Down -78.93% Since The Beginning Of The Year 2022/10/12 14:30:00 Marketing Sentinel
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has a beta value of 1.05 and has seen 1.04 million shares traded in the last trading session. The company, currently valued at $1.04B, closed the last trade at $6.62 per share which meant it lost -$0.27 on the day or -3.92% during that session. The ADPT stock price is -467.22% … Adaptive Biotechnologies Corporation Shares Are Down -78.93% Since The Beginning Of The Year Read More »
Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system 2022/10/11 13:48:25 Seeking Alpha
Adaptive Biotechnologies (ADPT) is collaborating with Epic to integrate the clonoSEQ Assay into Epic''s electronic medical record ((EMR)) system
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) Surged -21.77% In 6 Months – Here’s What To Expect Next 2022/10/08 14:00:00 Marketing Sentinel
During the last session, Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s traded shares were 0.82 million. At the end of the trading day, the stock’s price was $7.15, reflecting an intraday loss of -8.92% or -$0.7. The 52-week high for the ADPT share is $37.55, that puts it down -425.17 from that peak though still a striking 16.78% … Adaptive Biotechnologies Corporation (NASDAQ: ADPT) Surged -21.77% In 6 Months – Here’s What To Expect Next Read More »
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022 2022/10/05 20:05:31 Adaptive Biotechnologies
SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results
Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022 2022/10/05 20:05:00 GlobeNewswire
SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
How Could You Make A Quick Recovery From Adaptive Biotechnologies Corporation (NASDAQ: ADPT) Given A -120.07% Drop From Highs? 2022/08/05 15:00:00 Marketing Sentinel
During the last session, Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s traded shares were 2.39 million. At the end of the trading day, the stock’s price was $11.36, reflecting an intraday gain of 14.86% or $1.47. The 52-week high for the ADPT share is $40.00, that puts it down -252.11 from that peak though still a striking 47.62% … How Could You Make A Quick Recovery From Adaptive Biotechnologies Corporation (NASDAQ: ADPT) Given A -120.07% Drop From Highs? Read More »
Adaptive Biotechnologies Corporation (ADPT) Q2 2022 Earnings Call Transcript 2022/08/04 04:00:41 The Motley Fool
ADPT earnings call for the period ending June 30, 2022.
Adaptive Biotechnologies Corporation (ADPT) CEO Chad Robins on Q2 2022 Results - Earnings Call Transcript 2022/08/04 01:29:05 Seeking Alpha
Adaptive Biotechnologies Corporation (NASDAQ:NASDAQ:ADPT) Q2 2022 Results Conference Call August 03, 2022 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins -…
Adaptive Biotechnologies: Q2 Earnings Insights 2022/08/03 21:06:12 Benzinga
Adaptive Biotechnologies (NASDAQ: ADPT ) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Adaptive Biotechnologies beat estimated earnings by 13.95%, reporting an EPS of $-0.37 versus an … Full story available on Benzinga.com
Adaptive Biotechnologies GAAP EPS of -$0.37 beats by $0.05, revenue of $43.7M beats by $1.89M 2022/08/03 20:25:56 Seeking Alpha
Adaptive Biotechnologies press release (ADPT): Q2 GAAP EPS of -$0.37 beats by $0.05.Revenue of $43.7M (+13.5% Y/Y) beats by $1.89M.Adaptive Biotechnologies reiterates full year…